Anteris Technologies Global (NASDAQ:AVR) Stock Falls 7.5% After Analyst Downgrade

Anteris Technologies Global Corp. (NASDAQ:AVR – Get Free Report) shares fell 7.5% during trading on Friday after Barclays lowered their price target on the stock from $10.00 to $9.00. Barclays currently has an equal weight rating on the stock. Anteris Technologies Global traded as low as $5.38 and last traded at $5.42. 685,524 shares were traded during mid-day trading, a decline of 41% from the average daily volume of 1,155,886 shares. The stock had previously closed at $5.86.

AVR has been the topic of a number of other research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 price objective on shares of Anteris Technologies Global in a research report on Wednesday, October 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $13.75.

Get Our Latest Report on Anteris Technologies Global

Insiders Place Their Bets

In other Anteris Technologies Global news, major shareholder L1 Capital Pty Ltd bought 648,455 shares of Anteris Technologies Global stock in a transaction that occurred on Monday, October 5th. The shares were bought at an average cost of $7.51 per share, with a total value of $4,869,897.05. Following the transaction, the insider directly owned 12,778,380 shares of the company’s stock, valued at approximately $95,965,633.80. This represents a 5.35% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders acquired 1,554,730 shares of company stock worth $11,694,513. 4.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Anteris Technologies Global

Several hedge funds and other institutional investors have recently modified their holdings of AVR. Legal & General Group Plc acquired a new position in Anteris Technologies Global during the 2nd quarter valued at approximately $78,000. Bartlett & CO. Wealth Management LLC raised its holdings in shares of Anteris Technologies Global by 174.5% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 12,900 shares of the company’s stock worth $79,000 after purchasing an additional 8,200 shares during the last quarter. Greenline Wealth Management LLC acquired a new position in shares of Anteris Technologies Global in the 3rd quarter valued at about $88,000. Cetera Investment Advisers boosted its position in Anteris Technologies Global by 64.7% in the 1st quarter. Cetera Investment Advisers now owns 16,550 shares of the company’s stock worth $92,000 after purchasing an additional 6,500 shares in the last quarter. Finally, Kestra Advisory Services LLC acquired a new position in shares of Anteris Technologies Global in the 3rd quarter valued at $93,000.

Anteris Technologies Global Price Performance

The stock has a market capitalization of $528.40 million, a PE ratio of -3.37 and a beta of 2.02. The stock’s fifty day moving average is $6.96 and its 200-day moving average is $7.38.

Anteris Technologies Global (NASDAQ:AVR – Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. Anteris Technologies Global had a negative net margin of 4,637.48% and a negative return on equity of 57.15%. The business had revenue of $0.52 million during the quarter, compared to the consensus estimate of $2.75 million. On average, analysts forecast that Anteris Technologies Global Corp. will post -1.21 EPS for the current year.

Anteris Technologies Global Company Profile

(Get Free Report)

Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.

Read More

Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.